<DOC>
	<DOCNO>NCT01297933</DOCNO>
	<brief_summary>A compassionate use protocol provide Omegaven pediatric patient parenteral nutrition ( PN ) dependence parenteral nutrition associate liver disease ( PNALD ) .</brief_summary>
	<brief_title>Compassionate Use Omegaven Pediatric Patients With Parenteral Nutrition Associated Liver Disease</brief_title>
	<detailed_description>Omegaven intravenous fat emulsion ( IFE ) comprise omega-3 fatty acid derive fish oil . It use open label compassionate use treatment protocol , alternative soybean oil ( omega-6 ) , sole IFE source parenteral nutrition effort reduce and/or reverse parenteral nutrition associate liver disease . The study evaluate safety efficacy Omegaven use pediatric patient PN dependence PNALD .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>PN dependence due congenital acquire gastrointestinal disease Predicted PN requirement least additional 30 day Parenteral nutrition associate liver disease ( PNALD ) , define two conjugated bilirubin level &gt; = 2 mg/dL least one week apart , must obtain demonstrate persistence PNALD Failure respond standard therapy may include cycle PN , reduction dose soybean derive IFE , attempt advance enteral feed , ursodiol , metronidazole , avoidance excessive caloric provision sign parent legal guardian inform consent Acute treatable infection ( e.g . urinary tract infection , sepsis ) Known allergy egg fish protein Contraindications Omegaven Pregnancy Serum triglyceride level great 400 mg/dL baseline History severe hemolytic disorder INR great 1.5 baseline ( INR cutoff great 2 infant less 1 week age )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>parenteral nutrition associate liver disease</keyword>
	<keyword>cholestasis</keyword>
	<keyword>short bowel syndrome</keyword>
	<keyword>Omegaven</keyword>
</DOC>